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Vascular Smooth Muscle Cell Differentiation to an
Osteogenic Phenotype Involves TRPM7 Modulation
by Magnesium
Augusto C. Montezano, Deborah Zimmerman, Hiba Yusuf, Dylan Burger, Andreia Z. Chignalia,
Vishal Wadhera, Frank N. van Leeuwen, Rhian M. Touyz
Abstract—Arterial calcification, common in vascular diseases, involves vascular smooth muscle cell (VSMC) transfor-
mation to an osteoblast phenotype. Clinical studies suggest that magnesium may prevent this, but mechanisms are
unclear. We assessed whether increasing magnesium levels reduce VSMC calcification and differentiation and
questioned the role of the Mg2 transporter, transient receptor potential melastatin (TRPM)7 cation channels in this
process. Rat VSMCs were exposed to calcification medium in the absence and presence of magnesium (2.0 to
3.0 mmol/L) or 2-aminoethoxy-diphenylborate (2-APB) (TRPM7 inhibitor). VSMCs from mice with genetically low
(MgL) or high-normal (MgH) [Mg2]i were also studied. Calcification was assessed by von Kossa staining. Expression
of osteocalcin, osteopontin, bone morphogenetic protein (BMP)-2, BMP-4, BMP-7, and matrix Gla protein and activity
of TRPM7 (cytosol:membrane translocation) were determined by immunoblotting. Calcification medium induced
osteogenic differentiation, reduced matrix Gla protein content, and increased expression of the sodium-dependent
cotransporter Pit-1. Magnesium prevented calcification and decreased osteocalcin expression and BMP-2 activity and
increased expression of calcification inhibitors, osteopontin and matrix Gla protein. TRPM 7 activation was decreased
by calcification medium, an effect reversed by magnesium. 2-APB recapitulated the VSMC osteoblastic phenotype in
VSMCs. Osteocalcin was increased by calcification medium in VSMCs and intact vessels from MgL but not MgH,
whereas osteopontin was increased in MgH, but not in MgL mice. Magnesium negatively regulates vascular
calcification and osteogenic differentiation through increased/restored TRPM7 activity and increased expression of
anticalcification proteins, including osteopontin, BMP-7, and matrix Gla protein. New molecular insights are provided
whereby magnesium could protect against VSMC calcification. (Hypertension. 2010;56:453-462.)
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Vascular calcification, prevalent in patients with athero-sclerosis, aneurysms, diabetes, hypertension, and
chronic kidney disease (CKD), is associated with increased
risk of morbidity and mortality.1–5 Calcification contributes to
increased vascular stiffness, decreased elasticity and reduced
distensibility, characteristic features of the vascular pheno-
type in hypertension.6,7
Vascular calcification is a tightly regulated process similar
to bone formation.8 Factors promoting calcification include
abnormalities in mineral metabolism, particularly hyperphos-
phatemia and hypercalcemia.8 In the setting of magnesium
deficiency, this phenomenon may be exaggerated,9,10 with
studies demonstrating a positive correlation between hyper-
phosphatemia, hypercalcemia, and arterial calcification. In
vitro studies support these observations because exposure of
VSMCs to high phosphate and calcium concentrations show
a dose-dependent increase in mineralization, which is asso-
ciated with VSMC differentiation to an osteoblastic pheno-
type.11 This is driven by upregulation of transcription factors
such as cbfa1 (core-binding factor 1)/Runx2, MSX-2, and
bone morphogenetic protein (BMP)-2, involved in normal
bone development, and which control the expression of
osteogenic proteins, including osteocalcin, osteonectin, alka-
line phosphatase, collagen-1, and bone sialoprotein.12,13 In
culture, VSMCs can produce these bone-forming transcrip-
tion factors and proteins, an effect that is augmented with
high concentrations of phosphorous, calcium, cytokines,
glucose, oxidized lipids, and a low concentration of
magnesium.11 Another mechanism contributing to vascular
mineralization is loss of calcification inhibitors, such as
fetuin-A, matrix Gla protein, pyrophosphate, and
osteopontin.14,15
High phosphate and calcium levels promote VSMC differ-
entiation through various putative processes, including acti-
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vation of a type III sodium-dependent cotransporter, Pit-I,
which induces upregulation of cbfa1/Runx2,16,17 VSMC ves-
icle formation, which contain dysfunctional mineralization
inhibitors,18 dysregulation of vitamin D receptor (VDR), and
loss of functional calcium-sensing receptor.19 In addition,
decreased VSMC magnesium levels may be important, espe-
cially because magnesium antagonizes calcium effects.20 We
demonstrated that magnesium homeostasis in VSMCs is regu-
lated by the transient receptor potential melastatin (TRPM)7
cation channel and that in hypertension VSMC TRPM7 activity
and expression are downregulated.21–23 TRPM7, which com-
prises an ion channel, containing a magnesium-permeable pore,
fused to a kinase domain at the COOH terminus24 has been
implicated in osteoblast regulation.25
Clinically, management of vascular calcification is challeng-
ing. Antihypertensive treatment is associated with a reduced
calcium index and decreased carotid intima:media ratio in high
risk cardiovascular patients.26 In experimental hypertension
models, antihypertensive drugs prevent development of vascular
calcification and decrease pulse pressure.27 In CKD, phosphate
control with oral phosphate binders, including aluminum- and
calcium-based binders, is an important modality in the preven-
tion/regression of vascular calcification.28 However, these agents
have unwanted side effects, and as such, there has been interest
in alternative compounds, particularly magnesium-containing
phosphate binders.29
Considering the fact that in cardiovascular disease VSMC
[Mg2]i may be reduced, that low magnesium promotes
calcification, especially in the context of high phosphate and
calcium, that it is a very effective phosphate buffer and that it
is safe (even in patients with renal disease, if monitored
carefully) and inexpensive, magnesium may be an effective
modality to prevent or regress vascular calcification in
cardiovascular/renal disease. Here, we used an in vitro model
of VSMC calcification to assess whether magnesium attenu-
ates differentiation of VSMCs to an osteogenic phenotype
and investigated putative molecular mechanisms underlying
this process, focusing on TRPM7.
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Figure 1. Exposure of VSMCs to high phosphate/calcium levels induces calcification and an osteogenic phenotype. VSMCs from WKY
rats were exposed to calcification medium for 10 days. VSMCs were fixed and mineral deposition assessed by light microscopy using
von Kossa staining (A and B). No deposits were found in control conditions (A). Black deposits indicate deposits of phosphate-
containing mineral primarily in the extracellular regions (arrows) (B). C through G demonstrate expression of pro- and antiosteogenic
proteins: osteocalcin, BMP-2, BMP-4, and BMP7 in VSMCs grown in control (Ctl) and calcification (Ca) media. BMP2 homodimer and
reduced BMP-7 (active forms) were detected. D demonstrates expression of Pit-I. Immunoblots are representative of many blots. Open
bars represent VSMCs exposed to control medium and closed bars represent VSMCs exposed to calcification medium. Data are pre-
sented as osteogenic protein:-actin ratio. Results are meansSEM of 8 experiments. *P0.05 vs control.
454 Hypertension September 2010
 at Radboud Universiteit Nijmegen on November 1, 2012http://hyper.ahajournals.org/Downloaded from 
Methods
An expanded Methods section is available in the online Data
Supplement at http://hyper.ahajournals.org.
Cell Culture
VSMCs from WKY rats and from inbred mice (16 to 20 weeks old)
selected for high-normal (MgH) or low (MgL) intracellular magne-
sium levels were investigated.22,30,31
In Vitro and Ex Vivo Calcification
Calcification of VSMCs was induced by high phosphate calcium–
containing medium.32 In some experiments, cells were exposed to
calcification medium enriched with different concentrations of
Mg2: 2.0, 2.5, and 3.0 mmol/L for 10 days in the absence and
presence of the TRPM7 inhibitor 2-aminoethoxy-diphenylborate
(2-APB). Isolated aortas from MgH and MgL mice were exposed to
control or to calcification medium. Calcification was assessed by von
Kossa staining.
Statistical Analysis
Experiments were repeated 8 to 10 times in duplicate. Data are
expressed as meansSEM and were analyzed by ANOVA or by
unpaired Student’s t test as appropriate. P0.05 was significant.
Results
Exposure of VSMCs to High Phosphate and
Calcium Levels Induces Calcification
In VSMCs from WKY rats, Ca2-phosphate product accu-
mulation was induced by calcification medium. von Kossa–
positive staining for calcium was observed in only VSMCs
exposed to calcification medium (Figure 1A and 1B). Calci-
fication medium increased osteocalcin and Pit-I expression,
osteogenic markers, compared with control conditions (Fig-
ure 1C and 1D, P0.05). Expression of BPM-2 (Figure 1E)
and BMP-4 (Figure 1F) was also increased by calcification
medium. BMP-7 expression (Figure 1G) was decreased
(P0.05).
Magnesium Prevents VSMC-Induced Calcification
Magnesium dose-dependently reduced von Kossa–positive
staining in VSMCs exposed to calcification medium (Figure
2A through 2C). Osteocalcin expression increase was also
attenuated by magnesium (Figure 2D, P0.01). The calcifi-
cation process is an imbalance between production of proos-
teogenic factors and degradation of inhibitors of osteogenesis
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Figure 2. Magnesium attenuates VSMC mineralization effects of calcification medium. Treatment with magnesium concentration-
dependently (2.0 to 3.0 mmol/L) reduced von Kossa–positive staining in VSMCs exposed to calcification medium (A through C). Black
deposits indicate deposits of phosphate-containing mineral primarily in the extracellular regions (arrows). D demonstrates expression of
osteocalcin in VSMCs grown in control (Ctl) and calcification (Ca) media in the absence and presence of magnesium (Mg) (2.0 to
3.0 mmol/L). E shows osteopontin expression in VSMCs grown in control (Ctl) and calcification (Ca) media in the absence and pres-
ence of magnesium (Mg) (2.0 to 3.0 mmol/L). Top, Representative immunoblots. Bottom, Corresponding bar graphs. Data are osteocal-
cin or osteopontin:-actin ratio. Open bars represent VSMCs exposed to control medium and Mg2-enriched control medium (hashed
lines). Closed bars represent VSMCs exposed to calcification medium and Mg2-enriched calcification medium (hashed lines). Results
are meansSEM of 8 to 10 experiments. *P0.05 vs control; #P0.01 vs calcification group without magnesium.
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and calcium-phosphate product deposition. We assessed ex-
pression of osteopontin and matrix Gla-protein (MGP), anti-
calcification proteins, in VSMCs exposed to control and
calcification medium in the presence or absence of magne-
sium. Osteopontin content was unchanged by the calcification
medium compared with control (Figure 2E) but was increased
by magnesium (3.0 mmol/L) (P0.05). Matrix Gla protein
expression was decreased by the calcification medium (Fig-
ure 3), an effect that was reversed by magnesium.
Figure 4 demonstrates effects of magnesium on expression
of BMP-2 and BMP-7 in VSMCs exposed to calcification
medium. High phosphate and calcium medium increased
expression of the active form of BMP-2 (homodimer) (Figure
4A) and decreased expression of the proform and active form
(reduced) of BMP-7 (Figure 4B, P0.05), an effect reduced
by magnesium. Exposure of VSMCs to the calcification
medium also increased the precursor and mature form of
BMP-4 (Figure S1 in the online Data Supplement), an effect
reduced by magnesium treatment.
Calcification medium tended to increase Bax/Bcl-2 ratio,
and cleaved caspase 3/caspase 3 ratios, but significance was
not achieved. Mg2 did not alter Bax/Bcl-2 or caspase 3
regulation (Figure S2).
Dysregulation of the Mg2 Transporter TRPM7 Is
Associated With Calcification
TRPM7 translocation from cytosol to membrane, an indirect
measurement of transporter activity, was decreased by calci-
fication medium compared with control conditions (P0.05).
Magnesium prevented the decrease in TRPM7 activity in-
duced by calcification medium. The activity of TRPM7 was
unchanged by magnesium in control conditions (Figure 5A).
Despite changes in activity of the transporter, expression of
TRPM7 was not affected by any of the treatments (Figure S3).
To better understand whether TRPM7 plays a protective
role in vascular calcification, expression of osteocalcin,
osteopontin, and matrix Gla protein was evaluated in VSMCs
exposed to control and calcification medium containing
2-APB. As demonstrated in Figure 5B through 5D, treatment
with the TRPM7 inhibitor recapitulated the calcification
phenotype, where expression of osteocalcin was increased,
whereas that of osteopontin and matrix Gla protein was
decreased (P0.05). TRPM7 inhibition blocked the protec-
tive effect of magnesium as seen in 2-APB–treated cells
exposed to calcification medium plus magnesium
(3.0 mmol/L) (Figure 6A and 6B, P0.05).
VSMCs From MgL mice, but not MgH mice,
Exhibit an Osteogenic Phenotype
TRPM7 content was reduced by calcification medium in
VSMCs from MgL mice and MgH mice (Figure S4). In
VSMCs from MgL mice, but not from MgH mice, calcifica-
tion medium induced an increase in osteocalcin expression
(Figure 7A), whereas osteopontin expression was increased in
MgH VSMCs but not in MgL VSMCs (Figure 7B). Aortas
from MgH and MgL mice did not exhibit calcium deposits
when exposed to control medium. von Kossa–positive stain-
ing (Ca2 deposits) was observed in all aorta sections (6 of 6)
from MgL mice exposed to calcification medium (100%),
whereas only 1 aortic section (1 of 5) was positive for Ca2
deposits from MgH mice (20%) (Figure 8).
Discussion
Major findings from our study demonstrate that (1) a high
phosphate/high calcium milieu induces osteogenic transfor-
mation of VSMCs as evidenced by increased calcification,
upregulation of osteocalcin, BMP-2, BMP-4 and Pit-I, and
downregulation of BMP-7; (2) magnesium dose-dependently
attenuates VSMC calcification, an effect associated with
increased expression of the anticalcification protein os-
teopontin and upregulation of the calcification inhibitor
matrix Gla protein; (3) VSMC differentiation is associated
with decreased activation of TRPM7, which is reversed by
magnesium treatment; (4) TRPM7 inhibition in VSMCs
recapitulates the phenotype of calcified VSMCs; and (5)
VSMCs and intact vessels from MgH mice, but not from
MgL mice, are protected against osteogenic transforma-
tion. These observations highlight the novel findings that
magnesium has the potential to counteract molecular pro-
cesses associated with vascular calcification and that the
magnesium transporter TRPM7 may play a role in this
process (Figure S5).
Arterial calcification is not a homogenous entity, but a
complex manifestation influenced by derangements of cal-
cium and phosphate homeostasis and by an imbalance be-
tween calcification inhibitors and promoters.34 The in vitro
model studied here has many characteristics of human vas-
cular calcification in vivo. Of significance, the phosphate and
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Figure 3. Effects of magnesium on the calcification inhibitor
matrix Gla protein. VSMCs were exposed to calcification
medium in the absence and presence of magnesium. Open bars
represent VSMCs exposed to control medium and Mg2-
enriched control medium (hashed lines). Closed bars represent
VSMCs exposed to calcification medium and Mg2-enriched
calcification medium (hashed lines). Data are presented as
MGP:-actin ratios. Results are meansSEM of 8 to 10 experi-
ments. *P0.05 vs control; #P0.05 vs calcification group.
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calcium concentrations in the calcification-inducing medium
have clinical relevance because they are comparable to levels
observed in patients with hyperphosphatemia or in patients on
dialysis.35 VSMCs exposed to calcification medium demon-
strated granular deposits identified as phosphate-containing
mineral by von Kossa staining, as well as increased expres-
sion of osteocalcin, BMP-2, and BMP-4, osteogenic proteins
typically associated with osteoblastic differentiation and de-
creased expression of BMP-7 (also called osteogenic protein-
1), which is important in bone metabolism and antifibrotic
reactions. Moreover, expression of the sodium-dependent
cotransporter Pit-I was increased in calcified VSMCs, as
reported.16,17 Osteoblastic markers are also elevated in the
vasculature in experimental and clinical hypertension, diabe-
tes and uremia as well as in patients with CKD.36–40 Exposure
of VSMCs to increasing concentrations of magnesium was
associated with decreased calcification and reduced expres-
sion of osteogenic proteins, suggesting that magnesium in-
hibits calcification and osteoblast transformation of VSMCs.
Interestingly, magnesium alone increased expression of os-
teocalcin without an effect on calcification but when com-
bined with calcification medium, resulted in osteocalcin
downregulation, suggesting that interactions between magne-
sium, calcium and phosphate may be important in the final
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Figure 4. Effects of magnesium on expression of BMP-2 and BMP-7. VSMCs were exposed to calcification medium in the absence
and presence of increasing concentrations of magnesium. High phosphate and high calcium medium increased expression of the
active form of BMP-2 (homodimer) (A) and decreased expression of the proform and active form (reduced) of BMP-7 (B). Data are pre-
sented as BMP:-actin ratios. Open bars represent VSMCs exposed to control medium and Mg2-enriched control medium (hashed
lines). Closed bars represent VSMCs exposed to calcification medium and Mg2-enriched calcification medium (hashed lines). Results
are meansSEM of 8 to 10 experiments. *P0.05 vs control; #P0.05 vs calcification group.
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VSMC phenotype. The concentrations of magnesium used in
our study, 1.0 to 3.0 mmol/L, have (patho)physiological
relevance, because normal plasma levels range from 0.7 to
1.5 mmol/L and can be as high as 2.5 to 3.0 mmol/L in CKD.
Calcium phosphate crystals induce apoptosis, a process
that has been implicated in the initiation of VSMC transfor-
mation to an osteoblastic phenotype.41 However, unlike other
studies, we did not find a significant effect of calcification
medium on VSMC apoptosis, as assessed by Bax/Bcl and
cleaved caspase3/caspase 3 ratios. Reasons for this may relate
to differences in experimental protocols. Previous studies
assessed direct effects of calcium phosphate crystals on
VSMC growth/apoptosis and responses were investigated
within 72 hours of crystal exposure.41 In our studies, we did
not treat VSMCs with crystals, and our studies were con-
ducted over a longer time period.
Magnesium treatment was associated with an increase in
osteopontin expression. Osteopontin, initially identified in
osteoblasts as a mineralization-modulatory matrix protein,
has now been identified to be multifunctional.42 Although
osteopontin is considered as a proinflammatory and
proatherogenic molecule in inflammatory conditions, in vas-
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Figure 5. TRPM7 and calcification. A, TRPM7 activity in VSMCs as assessed by cytosol:membrane translocation. Top, Representative
immunoblot of TRPM7 expression in cytosol and membrane fractions. Bottom, Corresponding bar graph. Data are presented as mem-
brane TRPM7:cytosol TRPM7 content. Results are meansSEM of 8 to 10 experiments. *P0.05 vs control; #P0.05 vs calcification
group. B through D, Treatment with 2-APB recapitulated the calcification phenotype, where expression of osteocalcin was increased,
whereas that of osteopontin and MGP was decreased in VSMCs grown in control (Ctl) medium. Top, Representative immunoblots. Bot-
tom, Corresponding bar graphs. Open bars represent VSMCs exposed to control medium, whereas closed bars represent VSMCs
exposed to calcification medium and Mg2-enriched calcification medium (hashed lines). Data are presented as osteogenic protein:-
actin ratios. Results are meansSEM of 8 experiments. *P0.05 vs control.
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cular calcification, it acts as a negative regulator because it is
an inhibitor of calcification and an active inducer of decalci-
fication.42 Hence, our findings suggest that magnesium may
induce its protective effects, in part, by upregulating inhibi-
tors of calcification, such as osteopontin and BMP-7. This
was further confirmed by increased expression by magnesium
treatment of matrix Gla protein, an endogenous calcification
inhibitor.
The favorable anticalcification effects of magnesium are
also observed in vivo. In a rat model of aortic transplantation,
graft vessels exhibit massive media calcification and mineral
accumulation.43 This response was prevented by supplemen-
tation with magnesium, alkali citrate, and bases. In a model of
nephrocalcinosis, oral administration of magnesium blunted
progression of calcification.44 Clinical studies have also
shown protective anticalcification actions of magnesium.45 In
chronic dialysis patients, magnesium carbonate/calcium car-
bonate, used as a phosphate binder for 18 months, demon-
strated a small change in calcium index.46 Such observations
have prompted an interest in using magnesium salts as
phosphate binders, not only to treat hyperphosphatemia but
also to inhibit development or progression of vascular calci-
fication.30,47–49 In further support of our thesis that magne-
sium protects against vascular calcification are the findings
by Ishimura et al50 that in nondiabetic hemodialysis patients,
hypomagnesemia is associated with vascular calcification of
hand arteries, independent of serum calcium and phosphate
levels.
Exact mechanisms whereby magnesium interacts with
calcium and other ions in the setting of high phosphate is
complex, and we cannot rule out the possibility that there may
be direct competition between magnesium and calcium for
inorganic phosphate, which would reduce the calcium:phos-
phate interaction and hence alter the process of crystallization
of hydroxyapatite. Peters and Epple demonstrated that the
presence of additives, such as magnesium, distinctively alters
the morphology of calcium:phosphate crystals in proathero-
sclerotic conditions.51 von Kossa staining is not specific for
calcium but is specific for anions of salt. Hence, although we
cannot discern the exact composition of the crystals induced
by calcification medium, it is clear that magnesium reduces
the mineralization process in VSMCs. Future studies using
spectroscopy or diffractometry will enable better character-
ization of the crystal composition.
To explore in greater detail putative molecular mecha-
nisms underlying VSMC calcification in relation to
magnesium-sensitive processes, the role of TRPM7 was
probed. We focused on this chanzyme for three main
reasons: (1) TRPM7 is functionally involved in magne-
sium homeostasis in VSMCs33,52; (2) TRPM7 is regulated
by intracellular magnesium24; and (3) TRPM7 has recently
been implicated to play an important role in osteoclast and
osteoblast function.53 Calcification of VSMCs was associ-
ated with decreased activity of TRPM7, as evidenced by
decreased cytosol:membrane translocation. This may
translate into decreased transmembrane magnesium trans-
port. TRPM7 expression was unaltered by calcification
medium, and magnesium treatment had no effect on
TRPM7 content in calcified VSMCs. However, exposure
of cells to increasing magnesium concentrations restored
TRPM7 activity. Processes inducing blunting of TRPM7
activity are unclear but may relate to inhibitory actions of
high calcium in the calcification medium, because TRPM7
is negatively regulated by high intracellular cation levels.24
TRPM7 seems to be involved in the calcification/differen-
tiation process, because 2-APB, which inhibits TRPM7
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Figure 6. TRPM7 inhibition blocks the
protective effect of magnesium. Expres-
sion of osteocalcin (A) was increased and
that of MGP (B) was decreased in
2-APB–treated cells exposed to calcifica-
tion medium (Ca) plus magnesium
(3.0 mmol/L). Open bars represent
VSMCs exposed to control medium,
whereas closed bars represent VSMCs
exposed to calcification medium. Data
are normalized to -actin content.
Results are meansSEM of 8 experi-
ments. *P0.05 vs CaMg group in the
absence of 2-APB.
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activity and magnesium influx as we and others previously
demonstrated,21,54 recapitulated the osteoblast phenotype,
without protective actions of magnesium treatment. This is
evidenced by upregulation of osteocalcin and downregu-
lation of osteopontin and matrix Gla protein in control
conditions (without calcification medium), which mim-
icked effects in calcified VSMCs treated with magnesium.
Our novel findings highlight the potentially important role
of TRPM7 in calcification processes. Such phenomena
extend beyond the vasculature, as recently shown in
patients with osteoarthritis, where TRPM7 expression was
found to be altered in articular chondrocytes.55
To examine the significance of our findings in an animal
model of genetically low [Mg2]i, we investigated VSMCs
from MgL mice, which we previously characterized in
detail.30 These mice are hypomagnesemic, have increased
blood pressure, and display endothelial dysfunction and
vascular remodeling.30 VSMCs from MgL mice, but not
from MgH mice, when exposed to calcification medium,
exhibit features of osteogenesis, as evidenced by increased
osteocalcin, whereas VSMCs from MgH mice seem to be
protected by showing increased expression of the antios-
teogenic protein osteopontin. To further confirm the
(patho)physiological significance of this, we examined
effects of calcification medium on intact vessels from
MgH and MgL mice. Similar to our findings in VSMCs,
vessels from MgL were more susceptible to mineralization.
Taken together, these findings suggest that VSMCs from
mice that are hypomagnesemic (MgL) may be predisposed
to osteogenic transformation, whereas VSMCs from mice
with high-normal Mg2 (MgH) may be protected from this
process.
In summary, we demonstrate that high phosphate/calcium
induces VSMC calcification and differentiation to an osteo-
chondrogenic phenotype with associated decrease in TRPM7
activity. These processes were reversed by magnesium treat-
ment. Blocking activity of TRPM7 with 2-APB recapitulated
the osteogenic phenotype in VSMCs. Our findings suggest
that calcification is associated with TRPM7 downregulation,
and possibly associated decreased transcellular Mg2 trans-
port, an effect reversed by magnesium treatment. Our find-
ings identify TRPM7 as a potentially new molecular player in
VSMC calcification/osteogenic differentiation and suggest
that magnesium, possibly through restoration of TRPM7
activity, may be a useful modality in the treatment of vascular
calcification.
Perspectives
Identification of magnesium as a negative modulator of vascular
calcification and the potentially important role of TRPM7
in processes associated with transformation of VSMCs to
an osteogenic phenotype provide novel insights into mo-
lecular processes underlying vascular calcification. We
elucidate some possibilities whereby magnesium may
induce its protective actions: by increasing expression of
anticalcification modulators, by counteracting calcium ac-
tions, and by restoring TRPM7 activity. These findings
support the use of magnesium as a therapeutic strategy to
prevent/ameliorate vascular calcification in patients with
vascular disease.
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Figure 7. VSMCs from MgL mice, but not from MgH mice, exhibit
an osteogenic phenotype by calcification medium. Expression of
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days). Data are representative immunoblots, with corresponding
bar graphs from 4 to 6 experiments. Open bars represent VSMCs
exposed to control medium, whereas closed bars represent
VSMCs exposed to calcification medium. Data are presented as
protein:-actin ratios. Results are meansSEM of 8 to 10 experi-
ments. **P0.05 vs other groups.
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Methods 
Cell Culture 
This study was approved by the Animal Ethics Committee of the University of Ottawa and 
performed according to the recommendations of the Canadian Council for Animal Care. VSMCs 
derived from adult male WKY rats (16 weeks old) were studied. In addition VSMCs from inbred 
mice (16-20 weeks old) selected for normal-high (MgH) or low (MgL) intracellular magnesium levels 
were investigated (1,2). Mesenteric arteries were isolated and characterized as described in detail 
previously (3). Briefly, mesenteric beds were cleaned of adipose and connective tissue; VSMCs 
were dissociated by enzymatic digestion of vascular arcades for 60 minutes at 37°C. Cell 
suspension was centrifuged and resuspended in Dulbecco modified Eagle medium containing 
10% fetal calf serum, 2 mmol/L glutamine, 20 mmol/L HEPES (pH 7.4), and antibiotics. 
In vitro Calcification 
Calcification of VSMCs was induced by high phosphate- and high calcium-containing medium 
(4). When confluent, DMEM was changed to calcification medium, comprising DMEM (high 
glucose, 4.5 g/l) supplemented with 10% FBS, penicillin (100 U/ml), streptomycin (100 μg/ml), 
1.8 mmol/l CaCl2, 1 mmol/l sodium pyruvate, 2 mmol/L of inorganic phosphate. The medium 
was replaced with fresh medium every 2 days for a total of 10 days. In a different set of 
experiments, cells were exposed to the calcification or control medium enriched with different 
concentrations of Mg2+: 2.0, 2.5 and 3.0 mmol/L for 10 days. In some experiments VSMCs were 
exposed to the TRPM7 inhibitor 2-aminoethoxy-diphenylborate (2-APB) (10-6, 10-5 mol/L). 2-
APB was added to the medium during the last 3 days of incubation with control medium and the 
calcification medium containing 3.0 mmol/L of Mg2+. 
Von Kossa staining 
VSMC seeded on coverslips or deparaffinized paraffin sections were used. After rinsing in 
several changes of distilled water, sections were incubated with 1% silver nitrate solution in clear 
glass placed under ultraviolet light for 20 minutes. Coverslips and/or slides were again rinsed in 
several changes of distilled water. Unreacted silver was removed with 5% sodium thiosulfate for 
5 minutes. After washing with several changes of distilled water, coverslips and/or slides were 
counterstained with nuclear fast red for 5 minutes and prepared for microscopy (4,5). 
Western Blotting 
Proteins were extracted from VSMCs, separated by electrophoresis on a 10% polyacrylamide 
gel, and transferred onto a nitrocellulose membrane as previously described (6). Nonspecific 
binding sites were blocked with 5% skim milk in Tris-buffered saline solution with Tween for 1 
hour at 24°C. Membranes were then incubated with specific antibodies (1:1000) overnight at 
4°C. Antibodies were as follows: anti-osteocalcin (Santa Cruz), anti-osteopontin (OPN) (Santa 
Cruz), anti-BMP-2 (Santa Cruz), anti-BMP-4 (Santa Cruz), anti-BMP-7 (Santa Cruz), matrix gla 
protein (Sant Cruz), Pit-I (Santa Cruz), anti-Bcl-2 (Santa Cruz), anti-Bax (Cell Signaling), anti-
caspase 3/anti-cleaved caspase 3 (Cell Signaling) and anti-TRPM7 (from F. van Leeuwen 
Radboud University). After incubation with secondary antibodies, signals were revealed with 
chemiluminescence, visualized by autoradiography, and quantified densitometrically. Results 
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were normalized by the total protein and expressed as percentage of vehicle used in the 
experimental protocols. 
Ex vivo vascular calcification 
Under sterile conditions, aortas from MgH (5 animals) and MgL (6 animals) mice were gently 
stripped of excess adventitia and cut into 1-mm rings, as previously described (7). The aorta 
rings were placed in serum-free DMEM and incubated at 37°C in a 5% CO2 atmosphere with 
medium changes every 2 days. Two rings of each aorta from each animal were used. From those 
two rings, one ring was exposed to control medium (DMEM) and the other aorta ring was 
exposed to the calcification medium (DMEM supplemented with 1.8 mmol/l CaCl2, 1 mmol/l 
sodium pyruvate, 2 mmol/L of inorganic phosphate). Aorta were divided in 4 groups: MgH 
exposed to control medium, MgH exposed to calcification medium, MgL exposed to control 
medium and MgL exposed to calcification medium. Aorta rings were incubated for 10 d in these 
culture media for all experiments. Calcification was detected by Von Kossa staining. 
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Figure S1. Effects of magnesium on expression of BMP-4 in VSMCs exposed to 
calcification medium. VSMCs were exposed to control and calcification medium in the absence 
and presence of increasing concentrations of magnesium. High phosphate and high calcium 
medium increased expression of BMP-4 (pre-cursor and mature forms). Open bars represent 
VSMCs exposed to control medium and Mg2+-enriched control medium (hashed lines), whereas 
closed bars represent VSMCs exposed to calcification medium and Mg2+-enriched calcification 
medium (hashed lines). Data are presented as BMP:-actin ratio. Results are means  SEM of 6-
8 experiments. *p<0.05 vs control. # p<0.05 vs calcification group without magnesium. 
* * 
# 
# 
Ctl Ctl + Mg2+ Ca Ca + Mg2+ 
pro-BMP4 50 kDa 
mature BMP4 23 kDa 
-actin  42 kDa  
Figure S1
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Figure S2 – Effects of calcification medium on VSMC apoptosis. Bax/Bcl-2 and cleaved 
caspase-3/caspase 3 ratios in VSMCs exposed to control, calcification and Mg2+-enriched 
calcification medium. Calcification medium tended to increase Bax/Bcl-2 and cleaved caspase 
3/caspase 3 ratios, but significance was not achieved. Mg2+ treatment tended to decrease 
Bax/Bcl-2, but not cleaved caspase 3/caspase 3 ratio. Open bars represent VSMCs exposed to 
control medium, closed bars represent VSMCs exposed to calcification medium and Mg2+-
enriched calcification medium (hashed lines). Data are representative immunoblots, with 
corresponding bar graphs from 4-6 experiments. Results are means  SEM. 
Bax 23 kDa  
Bcl-2 26 kDa  
Cleaved Caspase 3 17 kDa 
Caspase 3 35 kDa  
A 
B 
Figure S2
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Figure S3. TRPM7 expression in VSMCs from WKY rats. TRPM7 expression in WKY 
VSMCs exposed to calcification medium in the absence and presence of increasing 
concentrations of magnesium. Calcification medium tended to decrease TRPM7 expression, but 
significance was not achieved. Open bars represent VSMCs exposed to control medium and 
Mg2+-enriched control medium (hashed lines), whereas closed bars represent VSMCs exposed to 
calcification medium and Mg2+-enriched calcification medium (hashed lines). Data are 
representative immunoblots, with corresponding bar graphs from 4-6 experiments. Results are 
means  SEM. 
 
 
 
Ctl Ctl + Mg2+ Ca Ca + Mg2+ 
TRPM 7 
220 kDa 
-actin 42 kDa  
Figure S3
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Figure S4. TRPM7 expression in VSMCs from MgH and MgL mice. TRPM7 content, 
evaluated in whole cell lysate, was reduced by calcification medium in VSMCs from MgL mice 
and MgH mice. Open bars represent VSMCs exposed to control medium and closed bars 
represent VSMCs exposed to calcification medium.  Data are representative immunoblots, with 
corresponding bar graphs from 4-6 experiments. *p<0.05 vs Control (Ctl) groups.  
 
 
 
 
 
 
Figure S4 
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Figure S5. Possible mechanisms whereby magnesium and TRPM7 influence calcification 
and osteogenic transformation of VSMCs. In the presence of a high phosphate/calcium milieu, 
VSMC undergo calcification and exhibit an osteoblast-like phenotype, characterized by 
increased expression of osteocalcin and BMP-2 and decreased expression of osteopontin and 
BMP-7. These phenomena are coupled to decreased activity of TRPM7. In the presence of 
increased extracellular magnesium, TRPM7 activity is restored. This is associated with 
decreased calcification, reduced expression of osteogenic proteins and increased osteopontin 
(OPN) content.  
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